CTL019: Phase IIa data

Data from 19 evaluable patients in a U.S. Phase IIa trial showed that CTL19 led to an ORR of 50% in patients with diffuse large B cell lymphoma (DLBCL) (n=12) and 100% in patients with follicular lymp...